AbbVie (NYSE:ABBV) Stock Jumps 2.9% - Still a Buy?

Key Points

• AbbVie shares rose 2.9% to about $294.15 in heavier-than-usual trading, with volume roughly 32% above its daily average.
• Recent quarterly results beat analyst estimates, and the company raised its quarterly dividend to $1.82 per share. Analysts’ consensus rating is “Moderate Buy,” with a $297.46 average price target.
• AbbVie is expanding its pipeline through a deal for an experimental IBD drug and an Oxford R&D investment, but it also discontinued a Phase 2 cancer-drug program. Some analysts warn the stock’s valuation may be stretched after its rally.

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s stock price shot up 2.9% on Wednesday. The stock traded as high as $295.40 and last traded at $294.1520. Approximately 8,407,818 shares traded hands during mid-day trading, an increase of 32% from the average daily volume of 6,347,137 shares. The stock had previously closed at $286.00.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie licensed global rights to Nxera Pharma’s experimental oral IBD candidate, NXE0033744. The agreement includes $100 million upfront and up to $1.37 billion in development and commercial milestones, plus royalties. The drug could add a new treatment option and diversify AbbVie’s growth pipeline, although it remains investigational. Nxera Pharma licensing announcement
• Positive Sentiment: AbbVie is investing more than £120 million to expand its Oxford R&D facility, supporting research in immunology, neurology and oncology. This is a longer-term investment in research capacity. Reuters article on Oxford R&D expansion
• Positive Sentiment: Several brokerages, including Morgan Stanley, raised their price targets, signaling improved analyst expectations. Morgan Stanley price-target article
• Neutral Sentiment: Updated 2026 guidance projects EPS of $13.95–$13.99, broadly in line with consensus, and revenue of $67.8 billion, slightly above expectations. Fourth-quarter revenue guidance is also a little ahead of consensus, but its EPS range is below analysts’ estimate.
• Negative Sentiment: AbbVie discontinued a Phase 2 solid-tumor drug program after seeing “limited benefit,” a setback for its oncology pipeline. Fierce Biotech article on the discontinued drug
• Negative Sentiment: One recent analysis cautioned that AbbVie’s valuation may be stretched after its rally, potentially limiting further upside if growth expectations are not met. Analysis of AbbVie’s valuation and outlook

Wall Street Analyst Weigh In

Several equities analysts have commented on ABBV shares. Sanford C. Bernstein reissued a "market perform" rating and set a $275.00 price objective on shares of AbbVie in a research report on Monday. Citigroup raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Argus upped their target price on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Piper Sandler raised their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. Finally, Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $297.46.

AbbVie Trading Up 2.9%

The business's 50-day moving average price is $270.23 and its 200-day moving average price is $237.89. The stock has a market cap of $519.70 billion, a PE ratio of 50.63, a P/E/G ratio of 1.31 and a beta of 0.20.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts' consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.86 earnings per share. As a group, analysts predict that AbbVie Inc. will post 14.00 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a $1.82 dividend. This is an increase from AbbVie's previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie's payout ratio is presently 119.10%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AbbVie

Institutional investors have recently added to or reduced their stakes in the business. Ranch Capital Advisors Inc. boosted its position in AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock worth $3,238,000 after acquiring an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK increased its stake in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company's stock worth $112,516,000 after acquiring an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in AbbVie in the 2nd quarter valued at about $23,557,000. Wedge Capital Management L L P NC increased its position in shares of AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock valued at $33,865,000 after acquiring an additional 9,380 shares during the last quarter. Finally, State Street Corp increased its holdings in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.